

Gertjan J L Kaspers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1300893/publications.pdf>

Version: 2024-02-01

519
papers

20,348
citations

11651

70
h-index

18647

119
g-index

529
all docs

529
docs citations

529
times ranked

21776
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell Sensitivity Assays: The MTT Assay. <i>Methods in Molecular Biology</i> , 2011, 731, 237-245.	0.9	1,474
2	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012, 120, 3187-3205.	1.4	451
3	Molecular basis of bortezomib resistance: proteasome subunit $\hat{1}^{25}$ (PSMB5) gene mutation and overexpression of PSMB5 protein. <i>Blood</i> , 2008, 112, 2489-2499.	1.4	406
4	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	1.4	383
5	Clinical implications of FLT3 mutations in pediatric AML. <i>Blood</i> , 2006, 108, 3654-3661.	1.4	355
6	Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 2591-2601.	1.6	287
7	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	1.6	277
8	Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90. <i>Journal of Clinical Oncology</i> , 2010, 28, 2339-2347.	1.6	265
9	NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. <i>Blood</i> , 2011, 118, 3645-3656.	1.4	250
10	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
11	In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma. <i>Cancer Cell</i> , 2010, 18, 244-257.	16.8	238
12	Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 1536-1542.	7.2	227
13	Computer Assisted Orthopaedic Surgery With Image Based Individual Templates. <i>Clinical Orthopaedics and Related Research</i> , 1998, 354, 28-38.	1.5	223
14	FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. <i>Blood</i> , 2003, 102, 2387-2394.	1.4	214
15	Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates. <i>Blood</i> , 1999, 94, 3121-3128.	1.4	213
16	Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology. <i>Cancer Treatment Reviews</i> , 2012, 38, 27-35.	7.7	199
17	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 599-607.	1.6	197
18	In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. <i>Blood</i> , 1995, 86, 3861-3868.	1.4	195

#	ARTICLE	IF	CITATIONS
19	A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 2026-2033.	1.4	177
20	Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 3262-3268.	1.6	164
21	Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. <i>Leukemia</i> , 2006, 20, 1217-1220.	7.2	162
22	Pediatric acute myeloid leukemia: international progress and future directions. <i>Leukemia</i> , 2005, 19, 2025-2029.	7.2	161
23	Impaired bortezomib binding to mutant β 5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. <i>Leukemia</i> , 2012, 26, 757-768.	7.2	155
24	Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. <i>Blood</i> , 2002, 99, 245-251.	1.4	153
25	Molecular basis of resistance to proteasome inhibitors in hematological malignancies. <i>Drug Resistance Updates</i> , 2015, 18, 18-35.	14.4	153
26	Prednisolone Resistance in Childhood Acute Lymphoblastic Leukemia: Vitro-Vivo Correlations and Cross-Resistance to Other Drugs. <i>Blood</i> , 1998, 92, 259-266.	1.4	151
27	Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. <i>The Cochrane Library</i> , 2017, 2017, CD008796.	2.8	151
28	Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. <i>Leukemia</i> , 2009, 23, 262-270.	7.2	143
29	Pediatric acute myeloid leukemia: towards high-quality cure of all patients. <i>Haematologica</i> , 2007, 92, 1519-1532.	3.5	142
30	Congenital leukaemia: the Dutch experience and review of the literature. <i>British Journal of Haematology</i> , 2002, 117, 513-524.	2.5	136
31	The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2005, 93, 1388-1394.	6.4	136
32	Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. <i>Blood</i> , 1995, 85, 751-756.	1.4	133
33	Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2009, 113, 2284-2289.	1.4	130
34	Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2005, 106, 717-720.	1.4	129
35	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. <i>Blood</i> , 2007, 109, 4641-4647.	1.4	126
36	Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. <i>Leukemia</i> , 2010, 24, 1422-1428.	7.2	124

#	ARTICLE	IF	CITATIONS
37	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. <i>Neuro-Oncology</i> , 2015, 17, 160-166.	1.2	124
38	Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 114-130.	4.4	124
39	Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia. <i>Blood</i> , 1999, 93, 1677-1683.	1.4	120
40	A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2205-2214.	1.4	120
41	Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. <i>Blood</i> , 2008, 111, 4322-4328.	1.4	118
42	The role of alternative splicing in cancer: From oncogenesis to drug resistance. <i>Drug Resistance Updates</i> , 2020, 53, 100728.	14.4	118
43	Psychosexual functioning of childhood cancer survivors. <i>Psycho-Oncology</i> , 2008, 17, 506-511.	2.3	115
44	Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. <i>British Journal of Cancer</i> , 1994, 70, 1047-1052.	6.4	114
45	The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates. <i>Cancer Research</i> , 2005, 65, 4425-4430.	0.9	114
46	Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. <i>Blood</i> , 2009, 113, 5951-5960.	1.4	112
47	In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma. <i>PLoS ONE</i> , 2013, 8, e61512.	2.5	108
48	Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1478-1487.	3.5	102
49	Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 53, 10-24.	7.7	101
50	Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 221-230.	3.5	98
51	Fatigue in children: reliability and validity of the Dutch PedsQLTM Multidimensional Fatigue Scale. <i>Quality of Life Research</i> , 2011, 20, 1103-1108.	3.1	98
52	In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. <i>British Journal of Cancer</i> , 1991, 64, 469-474.	6.4	96
53	Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. <i>Blood</i> , 2003, 101, 3868-3871.	1.4	94
54	Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. <i>Human Reproduction</i> , 2010, 25, 1520-1527.	0.9	94

#	ARTICLE	IF	CITATIONS
55	WEE1 inhibition sensitizes osteosarcoma to radiotherapy. <i>BMC Cancer</i> , 2011, 11, 156.	2.6	94
56	Hypofractionation vs Conventional Radiation Therapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Matched-Cohort Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 315-320.	0.8	92
57	Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia. <i>Blood</i> , 1998, 91, 2092-2098.	1.4	92
58	Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1281-1298.	3.8	90
59	Sleep, fatigue, depression, and quality of life in survivors of childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 479-485.	1.5	89
60	Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. , 1996, 27, 114-121.		87
61	The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. <i>Leukemia</i> , 2012, 26, 1313-1320.	7.2	86
62	Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients: Is it effective?. <i>Pediatric Blood and Cancer</i> , 2012, 58, 766-774.	1.5	85
63	PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. <i>Oncotarget</i> , 2011, 2, 984-996.	1.8	85
64	Glucocorticoid Resistance in Childhood Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 13, 187-201.	1.3	84
65	High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 1747-1754.	1.4	84
66	Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticoid resistance in childhood leukemia. <i>Leukemia</i> , 2004, 18, 530-537.	7.2	79
67	A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. <i>Cancer Research</i> , 2005, 65, 291-9.	0.9	79
68	Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 3-14.	2.5	77
69	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. <i>Haematologica</i> , 2014, 99, 865-872.	3.5	77
70	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. <i>British Journal of Haematology</i> , 2010, 148, 768-776.	2.5	75
71	Clinical Impact of Additional Cytogenetic Aberrations, <i>cKIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 4247-4258.	1.6	75
72	Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. <i>Scientific Reports</i> , 2016, 6, 25264.	3.3	75

#	ARTICLE	IF	CITATIONS
73	Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 384-392.	3.5	74
74	Subventricular spread of diffuse intrinsic pontine glioma. <i>Acta Neuropathologica</i> , 2014, 128, 605-607.	7.7	74
75	Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors. <i>CNS Drugs</i> , 2020, 34, 1121-1131.	5.9	73
76	High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. <i>Blood</i> , 2010, 116, 2752-2758.	1.4	71
77	Ethical issues at the interface of clinical care and research practice in pediatric oncology: a narrative review of parents' and physicians' experiences. <i>BMC Medical Ethics</i> , 2011, 12, 18.	2.4	71
78	Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. <i>Leukemia</i> , 1999, 13, 1574-1580.	7.2	69
79	EV11 overexpression in distinct subtypes of pediatric acute myeloid leukemia. <i>Leukemia</i> , 2010, 24, 942-949.	7.2	69
80	Abandonment of childhood cancer treatment in Western Kenya. <i>Archives of Disease in Childhood</i> , 2014, 99, 609-614.	1.9	69
81	Molecular Drug Imaging: ⁸⁹ Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 711-716.	5.0	69
82	The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. <i>Biochemical Pharmacology</i> , 2003, 65, 765-771.	4.4	67
83	Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. <i>Leukemia</i> , 2003, 17, 468-470.	7.2	65
84	WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 141-150.	4.1	64
85	Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 25.	2.4	63
86	Human pontine glioma cells can induce murine tumors. <i>Acta Neuropathologica</i> , 2014, 127, 897-909.	7.7	63
87	Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. <i>Blood</i> , 2002, 100, 3352-3360.	1.4	61
88	Interferon- β -induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. <i>Journal of Hematology and Oncology</i> , 2014, 7, 7.	17.0	61
89	Real-world implementation of electronic patient-reported outcomes in outpatient pediatric cancer care. <i>Psycho-Oncology</i> , 2017, 26, 951-959.	2.3	61
90	¹⁸ F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors. <i>Pediatric Radiology</i> , 2012, 42, 418-430.	2.0	60

#	ARTICLE	IF	CITATIONS
91	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011, 117, 7102-7111.	1.4	58
92	Cardiorespiratory fitness and physical activity in children with cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 2259-2268.	2.2	58
93	Longitudinal development of cancer-related fatigue and physical activity in childhood cancer patients. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27949.	1.5	58
94	Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients. <i>European Journal of Cancer</i> , 2017, 72, 235-243.	2.8	57
95	Blood pressure and body composition in long-term survivors of childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2012, 58, 278-282.	1.5	56
96	Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors. <i>Fertility and Sterility</i> , 2019, 111, 372-380.	1.0	56
97	Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. , 2013, , CD008796.		55
98	A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression. <i>PLoS ONE</i> , 2016, 11, e0153323.	2.5	55
99	High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. <i>Leukemia</i> , 2013, 27, 1497-1503.	7.2	54
100	Corruption in health-care systems and its effect on cancer care in Africa. <i>Lancet Oncology</i> , The, 2015, 16, e394-e404.	10.7	54
101	Loss of photoreceptoriness and gain of genomic alterations in retinoblastoma reveal tumor progression. <i>EBioMedicine</i> , 2015, 2, 660-670.	6.1	54
102	Monitoring of Tumor Growth and Post-radiation Recurrence in a Diffuse Intrinsic Pontine Glioma Mouse Model. <i>Brain Pathology</i> , 2011, 21, 441-451.	4.1	53
103	Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. <i>Haematologica</i> , 2013, 98, 1896-1904.	3.5	53
104	Why Pediatricians Fail to Diagnose Hypertension: A Multicenter Survey. <i>Journal of Pediatrics</i> , 2014, 164, 173-177.e7.	1.8	52
105	Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 1997, 25, 11-26.	4.4	51
106	Pediatric oncologists' attitudes towards involving adolescents in decision-making concerning research participation. <i>Pediatric Blood and Cancer</i> , 2010, 55, 123-128.	1.5	51
107	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2166-2174.	4.1	51
108	Two overlooked contributors to abandonment of childhood cancer treatment in Kenya: parents' social network and experiences with hospital retention policies. <i>Psycho-Oncology</i> , 2014, 23, 700-707.	2.3	50

#	ARTICLE	IF	CITATIONS
109	Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2016, 30, 1599-1603.	7.2	50
110	Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 61.	17.0	49
111	Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. <i>Human Reproduction</i> , 2018, 33, 1474-1488.	0.9	48
112	Pediatric acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 405-413.	2.4	47
113	The volume effect in paediatric oncology: a systematic review. <i>Annals of Oncology</i> , 2013, 24, 1749-1753.	1.2	47
114	<sc>CD</sc>45<sc>RA</sc>, a specific marker for leukaemia stem cell subpopulations in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 219-235.	2.5	47
115	Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. <i>Leukemia</i> , 2005, 19, 2063-2071.	7.2	46
116	Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. <i>British Journal of Cancer</i> , 2013, 109, 2142-2154.	6.4	46
117	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. <i>Blood</i> , 2018, 132, 405-412.	1.4	46
118	Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: Differential roles for CCR2, CCR5, CXCR4 and CXCR7. <i>Pediatric Blood and Cancer</i> , 2010, 55, 344-348.	1.5	45
119	High prevalence of complementary and alternative medicine use in the Dutch pediatric oncology population: a multicenter survey. <i>European Journal of Pediatrics</i> , 2013, 172, 31-37.	2.7	45
120	Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 673-689.	3.3	45
121	Signaling pathways and mesenchymal transition in pediatric high-grade glioma. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 871-887.	5.4	44
122	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 3319-3332.	7.0	44
123	Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. <i>Leukemia</i> , 2001, 15, 1066-1071.	7.2	43
124	Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. <i>European Journal of Cancer</i> , 2003, 39, 691-697.	2.8	43
125	Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. <i>Haematologica</i> , 2013, 98, 753-759.	3.5	43
126	Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2004, 100, 773-782.	4.1	42

#	ARTICLE	IF	CITATIONS
127	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. <i>Haematologica</i> , 2014, 99, 1472-1478.	3.5	42
128	Effects of a combined physical and psychosocial intervention program for childhood cancer patients on quality of life and psychosocial functioning: results of the QLIM randomized clinical trial. <i>Psycho-Oncology</i> , 2016, 25, 815-822.	2.3	42
129	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 255-266.	2.9	42
130	Classification Of Ex Vivo Methotrexate Resistance In Acute Lymphoblastic and Myeloid Leukaemia. <i>British Journal of Haematology</i> , 2000, 110, 791-800.	2.5	41
131	Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). <i>Biochemical Pharmacology</i> , 2004, 67, 1541-1548.	4.4	41
132	Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 103.	2.4	41
133	Cystatin C more accurately detects mildly impaired renal function than creatinine in children receiving treatment for malignancy. <i>Pediatric Blood and Cancer</i> , 2011, 57, 262-267.	1.5	41
134	A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 157-164.	2.4	41
135	Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2017, 2017, CD008727.	2.8	41
136	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019, 39, 215-225.	6.1	41
137	EFEMP1 induces β -secretase/Notch-mediated temozolomide resistance in glioblastoma. <i>Oncotarget</i> , 2014, 5, 363-374.	1.8	41
138	Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. <i>British Journal of Haematology</i> , 2000, 109, 427-429.	2.5	40
139	Proteasome inhibition as novel treatment strategy in leukaemia. <i>British Journal of Haematology</i> , 2006, 134, 253-262.	2.5	40
140	Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 599-604.	27.6	40
141	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1009-1018.	1.4	40
142	Antileukemic Activity and Mechanism of Drug Resistance to the Marine <i>Salinispora tropica</i> Proteasome Inhibitor Salinosporamide A (Marizomib). <i>Molecular Pharmacology</i> , 2014, 86, 12-19.	2.3	39
143	Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. <i>Leukemia</i> , 2019, 33, 1349-1359.	7.2	39
144	Attenuated AMPA Receptor Expression Allows Glioblastoma Cell Survival in Glutamate-Rich Environment. <i>PLoS ONE</i> , 2009, 4, e5953.	2.5	39

#	ARTICLE	IF	CITATIONS
145	Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 1-12.	2.3	38
146	Proteasome inhibitors in acute leukemia. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 327-337.	2.4	38
147	Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. <i>Arthritis and Rheumatism</i> , 2006, 54, 557-568.	6.7	37
148	Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. <i>British Journal of Cancer</i> , 2006, 94, 1837-1844.	6.4	37
149	Design of the Quality of Life in Motion (QLIM) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a combined physical exercise and psychosocial training program to improve physical fitness in children with cancer. <i>BMC Cancer</i> , 2010, 10, 624.	2.6	37
150	Adrenocortical carcinoma in children: First population-based clinicopathological study with long-term follow-up. <i>Oncology Reports</i> , 2014, 32, 2836-2844.	2.6	37
151	Factors influencing time to diagnosis and treatment among pediatric oncology patients in Kenya. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 186-199.	0.8	37
152	<i>CYP3A5</i> genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26854.	1.5	37
153	Effects of a combined physical and psychosocial training for children with cancer: a randomized controlled trial. <i>BMC Cancer</i> , 2018, 18, 1289.	2.6	37
154	Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2013, 27, 1786-1789.	7.2	36
155	Influence of health insurance access and hospital retention policies on childhood cancer treatment in Kenya. <i>Pediatric Blood and Cancer</i> , 2014, 61, 913-918.	1.5	36
156	Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. <i>Biochemical Pharmacology</i> , 2014, 89, 43-51.	4.4	36
157	Parental experiences of childhood cancer treatment in Kenya. <i>Supportive Care in Cancer</i> , 2015, 23, 1251-1259.	2.2	36
158	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. <i>Journal of Neuro-Oncology</i> , 2019, 145, 177-184.	2.9	36
159	Using Web-Based and Paper-Based Questionnaires for Collecting Data on Fertility Issues Among Female Childhood Cancer Survivors: Differences in Response Characteristics. <i>Journal of Medical Internet Research</i> , 2011, 13, e76.	4.3	36
160	Clinical and Cell Biological Features Related to Cellular Drug Resistance of Childhood Acute Lymphoblastic Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1995, 19, 407-416.	1.3	35
161	Pyuria is absent during urinary tract infections in neutropenic patients. <i>Pediatric Blood and Cancer</i> , 2011, 56, 868-870.	1.5	35
162	Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. <i>Scientific Reports</i> , 2014, 4, 5260.	3.3	35

#	ARTICLE	IF	CITATIONS
163	Height-Independent Estimation of Glomerular Filtration Rate in Children: An Alternative to the Schwartz Equation. <i>Journal of Pediatrics</i> , 2013, 163, 1722-1727.	1.8	34
164	Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance. <i>International Journal of Cancer</i> , 2016, 138, 1645-1656.	5.1	33
165	Gemtuzumab Ozogamicin (Mylotarg [®]) in Children with Refractory or Relapsed Acute Myeloid Leukemia. <i>Oncology Research and Treatment</i> , 2004, 27, 269-272.	1.2	32
166	In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. <i>Blood</i> , 2005, 106, 3532-3537.	1.4	32
167	miR-1 expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 328-339.	2.8	32
168	Delays in diagnosis and treatment of childhood cancer in Indonesia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2189-2196.	1.5	32
169	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2017, 96, 1449-1456.	1.8	32
170	Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the art. <i>Medical and Pediatric Oncology</i> , 1994, 22, 299-308.	1.0	31
171	Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. <i>British Journal of Cancer</i> , 2003, 88, 775-781.	6.4	31
172	Epidemiology of diagnosed childhood cancer in western kenya. <i>Archives of Disease in Childhood</i> , 2012, 97, 508-512.	1.9	31
173	Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. <i>Neuro-Oncology</i> , 2014, 16, 946-959.	1.2	31
174	Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?. <i>Haematologica</i> , 2008, 93, 1418-1420.	3.5	31
175	Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1552-1561.	4.1	30
176	Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. <i>Leukemia</i> , 2007, 21, 1584-1587.	7.2	30
177	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 5645-5657.	7.0	30
178	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	3.7	30
179	Socio-economic Status Plays Important Roles in Childhood Cancer Treatment Outcome in Indonesia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 6491-6496.	1.2	30
180	In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development. <i>Leukemia</i> , 2003, 17, 1338-1343.	7.2	29

#	ARTICLE	IF	CITATIONS
181	The influence of patient reported outcomes on the discussion of psychosocial issues in children with cancer. <i>Pediatric Blood and Cancer</i> , 2012, 59, 161-166.	1.5	29
182	(Immuno)proteasomes as therapeutic target in acute leukemia. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 599-615.	5.9	29
183	Wilms Tumor Treatment Outcomes: Perspectives From a Low-Income Setting. <i>Journal of Global Oncology</i> , 2017, 3, 555-562.	0.5	29
184	Different expression of glutathione S-transferase \pm , $\frac{1}{4}$ and $\text{I}\epsilon$ in childhood acute lymphoblastic and myeloid leukaemia. <i>British Journal of Haematology</i> , 1999, 104, 321-327.	2.5	28
185	Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2004, 127, 264-279.	2.5	28
186	Costâ€effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: The influence of new medication and diagnostic technology. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1005-1010.	1.5	28
187	A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. <i>BMC Cancer</i> , 2012, 12, 363.	2.6	28
188	Malignant melanoma as second malignant neoplasm in longâ€term childhood cancer survivors: A systematic review. <i>Pediatric Blood and Cancer</i> , 2012, 58, 665-674.	1.5	28
189	Clinical challenges in <i>de novo</i> pediatric acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 277-293.	2.4	28
190	Drug combination testing in acute lymphoblastic leukemia using the MTT assay. <i>Leukemia Research</i> , 1995, 19, 175-181.	0.8	27
191	Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2005, 41, 1300-1303.	2.8	27
192	High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. <i>Leukemia</i> , 2010, 24, 2048-2055.	7.2	27
193	How I treat paediatric relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 636-645.	2.5	27
194	Improved outcome at end of treatment in the collaborative Wilms tumour Africa project. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26945.	1.5	27
195	Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2018, 183, 512-516.	2.5	27
196	No Prognostic Impact of the <i>WT1</i> Gene Single Nucleotide Polymorphism rs16754 in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, e523-e526.	1.6	26
197	Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. <i>Experimental Cell Research</i> , 2017, 360, 397-403.	2.6	26
198	Responseâ€guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AMLâ€01. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27605.	1.5	26

#	ARTICLE	IF	CITATIONS
199	Gender-specific differences in parental health-related quality of life in childhood cancer. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27728.	1.5	26
200	Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. <i>Cellular Oncology</i> , 2008, 30, 299-306.	1.9	26
201	Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. <i>Leukemia</i> , 2008, 22, 2284-2285.	7.2	25
202	Effects of Growth Hormone Therapy on Bone Mass, Metabolic Balance, and Well-Being in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e231-e238.	0.6	25
203	High resolution SNP array profiling identifies variability in retinoblastoma genome stability. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 1-14.	2.8	25
204	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. <i>Neuro-Oncology</i> , 2016, 18, 582-588.	1.2	25
205	A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2017, 135, 307-315.	2.9	25
206	Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates. <i>Frontiers in Oncology</i> , 2017, 7, 254.	2.8	25
207	Reproductive intentions and use of reproductive health care among female survivors of childhood cancer. <i>Human Reproduction</i> , 2018, 33, 1167-1174.	0.9	25
208	Sleep-wake rhythm disruption is associated with cancer-related fatigue in pediatric acute lymphoblastic leukemia. <i>Sleep</i> , 2020, 43, .	1.1	25
209	A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. <i>Virology</i> , 2007, 361, 56-67.	2.4	24
210	Hypothalamic-pituitary-adrenal axis function in survivors of childhood acute lymphoblastic leukemia and healthy controls. <i>Psychoneuroendocrinology</i> , 2012, 37, 1448-1456.	2.7	24
211	Implementation of a multi-institutional diffuse intrinsic pontine glioma autopsy protocol and characterization of a primary cell culture. <i>Neuropathology and Applied Neurobiology</i> , 2013, 39, 426-436.	3.2	24
212	Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?. <i>Supportive Care in Cancer</i> , 2014, 22, 3-6.	2.2	24
213	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 612-615.	5.0	24
214	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. <i>Haematologica</i> , 2018, 103, 1484-1492.	3.5	24
215	Alpe d'Au TM HuZes Cancer Rehabilitation (A-CaRe) Research: Four Randomized Controlled Exercise Trials and Economic Evaluations in Cancer Patients and Survivors. <i>International Journal of Behavioral Medicine</i> , 2012, 19, 143-156.	1.7	23
216	Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 19, 518-530.	1.3	23

#	ARTICLE	IF	CITATIONS
217	Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	23
218	Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. <i>EBioMedicine</i> , 2019, 50, 81-92.	6.1	23
219	Determinants of health-related quality of life proxy rating disagreement between caregivers of children with cancer. <i>Quality of Life Research</i> , 2020, 29, 901-912.	3.1	23
220	High prevalence of parent-reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28165.	1.5	23
221	Pediatric relapsed acute myeloid leukemia: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 45-52.	2.4	23
222	Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-l-aspartate in human leukemic blast cells and cell lines. <i>Leukemia Research</i> , 1996, 20, 127-134.	0.8	22
223	Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 924-930.	7.0	22
224	Paraneoplastic gastro-intestinal anti-Hu syndrome in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2009, 52, 396-398.	1.5	22
225	Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. <i>British Journal of Haematology</i> , 2014, 166, 902-910.	2.5	22
226	Convection enhanced delivery of carmustine to the murine brainstem: A feasibility study. <i>Journal of Neuroscience Methods</i> , 2014, 238, 88-94.	2.5	22
227	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 82.	17.0	22
228	Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in ZMYND11/MBTD1 fusion. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 237-241.	2.8	22
229	RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. <i>Blood</i> , 2018, 131, 2485-2489.	1.4	22
230	Gene Expression Profiles Associated with Pediatric Relapsed AML. <i>PLoS ONE</i> , 2015, 10, e0121730.	2.5	22
231	External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. <i>Journal of Neuro-Oncology</i> , 2017, 134, 231-240.	2.9	21
232	SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings. <i>Pediatric Blood and Cancer</i> , 2023, 70, e28087.	1.5	21
233	MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 58-69.	1.2	21
234	In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. <i>Haematologica</i> , 2006, 91, 17-23.	3.5	21

#	ARTICLE	IF	CITATIONS
235	Childhood Lymphomatoid Granulomatosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e416-e422.	0.6	20
236	Screening for Psychosocial Risk in Dutch Families of a Child With Cancer: Reliability, Validity, and Usability of the Psychosocial Assessment Tool. <i>Journal of Pediatric Psychology</i> , 2016, 41, 810-819.	2.1	20
237	BCL-2 Expression in Childhood Leukemia Versus Spontaneous Apoptosis, Drug Induced Apoptosis, and in vitro Drug Resistance. <i>Advances in Experimental Medicine and Biology</i> , 1999, 457, 325-333.	1.6	20
238	MicroRNA-106b~25 cluster is upregulated in relapsed <i>MLL</i>-rearranged pediatric acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 48412-48422.	1.8	20
239	Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. <i>Oncotarget</i> , 2017, 8, 60447-60452.	1.8	20
240	The evolution of comprehensive cancer care in Western Kenya. <i>Journal of Cancer Policy</i> , 2013, 1, e25-e30.	1.4	19
241	Validity of self-reported data on pregnancies for childhood cancer survivors: a comparison with data from a nationwide population-based registry. <i>Human Reproduction</i> , 2013, 28, 819-827.	0.9	19
242	EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System. <i>Molecular Cancer Research</i> , 2015, 13, 982-992.	3.4	19
243	Preclinical therapeutic targets in diffuse midline glioma. <i>Drug Resistance Updates</i> , 2019, 44, 15-25.	14.4	19
244	A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. <i>European Journal of Cancer</i> , 2001, 37, 492-498.	2.8	18
245	High-quality care for all children with cancer. <i>Annals of Oncology</i> , 2012, 23, 1906-1911.	1.2	18
246	Health Status Utilities in Pediatrics. <i>Medical Decision Making</i> , 2014, 34, 21-32.	2.4	18
247	Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia. <i>Supportive Care in Cancer</i> , 2014, 22, 3235-3242.	2.2	18
248	Factors influencing childhood cancer patients to participate in a combined physical and psychosocial intervention program: Quality of Life in Motion. <i>Psycho-Oncology</i> , 2015, 24, 465-471.	2.3	18
249	State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. <i>Journal of Neuro-Oncology</i> , 2016, 128, 387-394.	2.9	18
250	Influence of health insurance status on paediatric non-Hodgkinâ€™s lymphoma treatment in Kenya. <i>BMJ Paediatrics Open</i> , 2017, 1, e000149.	1.4	18
251	Efficacy and safety of recombinant <i>E. coli</i> asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27083.	1.5	18
252	Validation of the PROMIS Sleep Disturbance and Sleep-Related Impairment item banks in Dutch adolescents. <i>Quality of Life Research</i> , 2018, 27, 1911-1920.	3.1	18

#	ARTICLE	IF	CITATIONS
253	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. <i>Cancers</i> , 2020, 12, 1789.	3.7	18
254	The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study. <i>BMC Pediatrics</i> , 2008, 8, 25.	1.7	17
255	High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). <i>Blood</i> , 2011, 117, 928-935.	1.4	17
256	A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer. <i>Oncotarget</i> , 2016, 7, 35776-35788.	1.8	17
257	The association of aberrant folypolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, e291-e294.	3.5	17
258	Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 137-146.	2.4	17
259	Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation. <i>Leukemia Research</i> , 2019, 79, 45-51.	0.8	17
260	Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28099.	1.5	17
261	The impact of maintenance therapy on sleep-wake rhythms and cancer-related fatigue in pediatric acute lymphoblastic leukemia. <i>Supportive Care in Cancer</i> , 2020, 28, 5983-5993.	2.2	17
262	CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. <i>Oncology Reports</i> , 2008, 19, 1517-23.	2.6	16
263	Health-related quality of life and utility scores in short-term survivors of pediatric acute lymphoblastic leukemia. <i>Quality of Life Research</i> , 2013, 22, 677-681.	3.1	16
264	MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 222-230.	6.4	16
265	Content validity of the Patient-Reported Outcomes Measurement Information System Sleep Disturbance and Sleep Related Impairment item banks in adolescents. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 92.	2.4	16
266	A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26651.	1.5	16
267	Concurrence of sleep problems and distress: prevalence and determinants in parents of children with cancer. <i>HÅrre Utbildning</i> , 2019, 10, 1639312.	3.0	16
268	COVID-19: how will this impact children with cancer, now and in the future?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 527-529.	2.4	16
269	Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation. <i>Cancers</i> , 2020, 12, 723.	3.7	16
270	Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. <i>Oncotarget</i> , 2016, 7, 74779-74796.	1.8	16

#	ARTICLE	IF	CITATIONS
271	Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in <i>In Vitro</i> Cancer Models. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	16
272	Coxsackievirus and Adenovirus Receptor Expression on Primary Osteosarcoma Specimens and Implications for Gene Therapy with Recombinant Adenoviruses. <i>Clinical Cancer Research</i> , 2005, 11, 2445-2448.	7.0	15
273	Intravenous administration of the conditionally replicative adenovirus Ad5- β 24RGD induces regression of osteosarcoma lung metastases. <i>Molecular Cancer</i> , 2008, 7, 9.	19.2	15
274	Effect of corruption on medical care in low-income countries. <i>Pediatric Blood and Cancer</i> , 2012, 58, 325-326.	1.5	15
275	Engagement of SIRP α Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells. <i>PLoS ONE</i> , 2013, 8, e52143.	2.5	15
276	Patient reported outcomes in pediatric oncology practice: Suggestions for future usage by parents and pediatric oncologists. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1707-1710.	1.5	15
277	Executive Dysfunction 25 Years after Treatment with Cranial Radiotherapy for Pediatric Lymphoid Malignancies. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 657-669.	1.8	15
278	The prevalence and risk factors of sleep problems in pediatric oncology: its effect on quality of life during and after cancer treatment. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 153-171.	0.6	15
279	Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia – a review. <i>British Journal of Haematology</i> , 2017, 176, 168-178.	2.5	15
280	3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. <i>European Journal of Cancer</i> , 2018, 90, 102-110.	2.8	15
281	A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2021, 153, 263-271.	2.9	15
282	Healthcare providers' perspectives on childhood cancer treatment in Manado, Indonesia. <i>Psycho-Oncology</i> , 2013, 22, 2522-2528.	2.3	14
283	Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. <i>British Journal of Haematology</i> , 2016, 175, 588-601.	2.5	14
284	Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1457-1460.	1.5	14
285	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. <i>Haematologica</i> , 2017, 102, 552-561.	3.5	14
286	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26664.	1.5	14
287	A cost-effectiveness analysis of <i>Erwinia</i> asparaginase therapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27458.	1.5	14
288	Measuring vincristine-induced peripheral neuropathy in children with cancer: validation of the Dutch pediatric modified Total Neuropathy Score. <i>Supportive Care in Cancer</i> , 2020, 28, 2867-2873.	2.2	14

#	ARTICLE	IF	CITATIONS
289	Kaposiform (Spindle Cell) Hemangioendotelioma in a Child With an Unusual Presentation. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 240-242.	0.6	13
290	Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. , 2012, , CD008727.		13
291	Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. <i>Expert Review of Hematology</i> , 2014, 7, 791-805.	2.2	13
292	Applicability and evaluation of a psychosocial intervention program for childhood cancer patients. <i>Supportive Care in Cancer</i> , 2015, 23, 2327-2333.	2.2	13
293	Healthcare providers' perspectives on traditional and complementary alternative medicine of childhood cancer in Kenya. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27309.	1.5	13
294	Development of an evidence-based decision aid on complementary and alternative medicine (CAM) and pain for parents of children with cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 2415-2429.	2.2	13
295	Working Together to Build a Better Future for Children With Cancer in Africa. <i>JCO Global Oncology</i> , 2020, 6, 1076-1078.	1.8	13
296	Actigraphic estimates of sleep and the sleep-wake rhythm, and 6-sulfatoxymelatonin levels in healthy Dutch children. <i>Chronobiology International</i> , 2020, 37, 660-672.	2.0	13
297	Radiosensitization in Pediatric High-Grade Glioma: Targets, Resistance and Developments. <i>Frontiers in Oncology</i> , 2021, 11, 662209.	2.8	13
298	Clinical Significance of Cellular Drug Resistance in Childhood Leukemia. <i>Recent Results in Cancer Research</i> , 2003, 161, 196-220.	1.8	13
299	Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay. <i>Blood</i> , 1999, 93, 1067-1074.	1.4	13
300	The association between vincristine-induced peripheral neuropathy and health-related quality of life in children with cancer. <i>Cancer Medicine</i> , 2021, 10, 8172-8181.	2.8	13
301	Potential of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2005, 131, 219-222.	2.5	12
302	Psychometric properties and Dutch norm values of the Children's Sleep Habits Questionnaire in toddlers. <i>Sleep Medicine</i> , 2017, 34, 57-63.	1.6	12
303	An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 523-527.	2.5	12
304	An efficient method for the transduction of primary pediatric glioma neurospheres. <i>MethodsX</i> , 2018, 5, 173-183.	1.6	12
305	Influence of health insurance status on childhood cancer treatment outcomes in Kenya. <i>Supportive Care in Cancer</i> , 2020, 28, 917-924.	2.2	12
306	Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial). <i>Cancers</i> , 2020, 12, 3745.	3.7	12

#	ARTICLE	IF	CITATIONS
307	Psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance and Sleep-Related Impairment item banks in adolescents. <i>Journal of Sleep Research</i> , 2021, 30, e13029.	3.2	12
308	In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997, 90, 2723-2729.	1.4	12
309	Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor α and glucocorticoid induced apoptosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1289-1295.	0.9	11
310	Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs). <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 212-220.	1.7	11
311	Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and BclI. <i>Haematologica</i> , 2014, 99, e136-e137.	3.5	11
312	Cost-effectiveness of a combined physical exercise and psychosocial training intervention for children with cancer: Results from the quality of life in motion study. <i>European Journal of Cancer Care</i> , 2017, 26, e12586.	1.5	11
313	Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 81, 27-34.	0.8	11
314	Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 1999, 78, 163-171.	1.8	10
315	Folates and antifolates in the treatment of cancer; role of folic acid supplementation on efficacy of folate and non-folate drugs. <i>Trends in Food Science and Technology</i> , 2005, 16, 289-297.	15.1	10
316	Central nervous system involvement in relapsed acute promyelocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2009, 53, 235-236.	1.5	10
317	What Constitutes the Best Interest of a Child? Views of Parents, Children, and Physicians in a Pediatric Oncology Setting. <i>American Journal of Bioethics Primary Research</i> , 2013, 4, 1-10.	1.5	10
318	Assessment of Mercaptopurine (6MP) Metabolites and 6MP Metabolic Key-Enzymes in Childhood Acute Lymphoblastic Leukemia. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014, 33, 422-433.	1.1	10
319	Fertility studies in female childhood cancer survivors: selecting appropriate comparison groups. <i>Reproductive BioMedicine Online</i> , 2014, 29, 352-361.	2.4	10
320	Acute myeloid leukaemia niche regulates response to L-asparaginase. <i>British Journal of Haematology</i> , 2019, 186, 397-399.	2.5	10
321	Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML01. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27701.	1.5	10
322	Parental functioning during maintenance treatment for childhood acute lymphoblastic leukemia: Effects of treatment intensity and dexamethasone pulses. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28697.	1.5	10
323	Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 765-780.	2.4	10
324	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 612.	3.7	10

#	ARTICLE	IF	CITATIONS
325	AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. <i>IScience</i> , 2022, 25, 104398.	4.1	10
326	A new era for children with diffuse intrinsic pontine glioma: hope for cure?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1109-1112.	2.4	9
327	No Efficacy for Silicone Gel Sheeting in Prevention of Abnormal Scar Formation in Children with Cancer. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 1086-1094.	1.4	9
328	SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2698-2702.	7.2	9
329	Immunocytochemical Detection of hENT1 and hCNT1 in Normal Tissues, Lung Cancer Cell Lines, and NSCLC Patient Samples. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2008, 27, 787-793.	1.1	8
330	Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2015, , CD008727.	2.8	8
331	Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A <sc>NOPHO</sc>-â€<sc>DBH</sc>-â€<sc>AML</sc> study. <i>British Journal of Haematology</i> , 2018, 183, 618-628.	2.5	8
332	Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27231.	1.5	8
333	Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlinâ€“FrankfÃ¼rtâ€“MÃ¼nster (Iâ€“BFM</sc>) study group. <i>British Journal of Haematology</i> , 2018, 183, 87-95.	2.5	8
334	Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 6634-6643.	2.8	8
335	Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 1247.	3.7	8
336	Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2403-2406.	7.2	8
337	Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. <i>Cells</i> , 2021, 10, 665.	4.1	8
338	Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. <i>Cancers</i> , 2021, 13, 4598.	3.7	8
339	Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Report of the International Randomised Phase III Study Relapsed AML 2001/01.. <i>Blood</i> , 2006, 108, 2013-2013.	1.4	8
340	Imaged-guided focused ultrasound in combination with various formulations of doxorubicin for the treatment of diffuse intrinsic pontine glioma. <i>Translational Medicine Communications</i> , 2022, 7, .	1.4	8
341	Modulation of Cytarabine Induced Cytotoxicity Using Novel Deoxynucleoside Analogs in the HL60 Cell Line. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1513-1516.	1.1	7
342	Treatment of childhood acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 917-929.	2.4	7

#	ARTICLE	IF	CITATIONS
343	FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. <i>Leukemia Research</i> , 2010, 34, 1302-1307.	0.8	7
344	CBL mutations do not frequently occur in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 577-584.	2.5	7
345	Healthcare providers' perspectives on health insurance access, waiving procedures, and hospital detention practices in Kenya. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27221.	1.5	7
346	A meta-analysis of accelerometer sleep outcomes in healthy children based on the Sadeh algorithm: the influence of child and device characteristics. <i>Sleep</i> , 2021, 44, .	1.1	7
347	Measurable residual disease in pediatric acute myeloid leukemia: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 451-459.	2.4	7
348	Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML. <i>Blood</i> , 2014, 124, 924-924.	1.4	7
349	Parents' and Health-Care Providers' Perspectives on Side-Effects of Childhood Cancer Treatment in Indonesia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3593-3599.	1.2	7
350	Immunocytochemical Detection of Deoxycytidine Kinase in Pediatric Malignancies in Relation to In Vitro Cytarabine Sensitivity. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1351-1356.	1.1	6
351	Online Fluorescent Method to Assess BCRP/ABCG2 Activity in Suspension Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1451-1454.	1.1	6
352	Strategies for the analysis of in vitro radiation sensitivity and prediction of interaction with potential radiation modifying agents. <i>International Journal of Radiation Biology</i> , 2010, 86, 458-466.	1.8	6
353	Comparing Healthcare Providers' Perspectives on Complementary and Alternative Medicine in Childhood Cancer Between Netherlands and Indonesia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 118-123.	1.5	6
354	TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 736-739.	2.5	6
355	Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 1379-1388.	1.1	6
356	Role of Folylpolylglutamate Synthetase and Folylpolylglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia. <i>Blood</i> , 1999, 93, 1677-1683.	1.4	6
357	Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study. <i>Blood</i> , 2012, 120, 538-538.	1.4	6
358	Impact of COVID-19 measures on a paediatric oncology outreach program. <i>Psycho-Oncology</i> , 2022, 31, 860-864.	2.3	6
359	Past, current and future protocols for combined modality therapy in childhood medulloblastoma. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 79-90.	2.4	5
360	Circumvention of glucocorticoid resistance in childhood leukemia. <i>Leukemia Research</i> , 2008, 32, 1417-1423.	0.8	5

#	ARTICLE	IF	CITATIONS
361	Is aggressive local treatment necessary for diffuse liver involvement in patients with progression of stage 4s neuroblastoma to stage 4?. <i>Journal of Pediatric Surgery</i> , 2008, 43, 1630-1635.	1.6	5
362	Genomic landscape of retinoblastoma in <i>Rb^{+/+}p130^{+/+}</i> mice resembles human retinoblastoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 231-242.	2.8	5
363	Does the guided online cognitive behavioral therapy for insomnia <i>“Sleep youth”</i> improve sleep of adolescents and young adults with insomnia after childhood cancer? (MICADO-study): study protocol of a randomized controlled trial. <i>Trials</i> , 2021, 22, 307.	1.6	5
364	Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. <i>Cancers</i> , 2021, 13, 4364.	3.7	5
365	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29341.	1.5	5
366	Female reproductive function after treatment of childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28894.	1.5	5
367	Excellent Outcome in Pediatric AML with Response Guided Chemotherapy without Allogeneic HSCT in First Complete Remission: Results from Protocol DB-AML01. <i>Blood</i> , 2015, 126, 2506-2506.	1.4	5
368	Parental Experiences with Chemotherapy-Induced Alopecia among Childhood Cancer Patients in Indonesia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 1717-1723.	1.2	5
369	Microrna-106b-25 Cluster Is Involved in Relapsed MLL-Rearranged Pediatric AML. <i>Blood</i> , 2014, 124, 1038-1038.	1.4	5
370	Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHO <i>“SHIP”</i> consortium. <i>British Journal of Haematology</i> , 2022, , .	2.5	5
371	Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: A Dutch population-based study. <i>International Journal of Cancer</i> , 2022, 150, 1101-1112.	5.1	5
372	Outcomes of Wilms tumor treatment in western Kenya. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29503.	1.5	5
373	Parental Sleep, Distress, and Quality of Life in Childhood Acute Lymphoblastic Leukemia: A Longitudinal Report from Diagnosis up to Three Years Later. <i>Cancers</i> , 2022, 14, 2779.	3.7	5
374	Cellular drug resistance in childhood leukemia. <i>Annals of Hematology</i> , 1994, 69, S31-S34.	1.8	4
375	Medulloblastoma: need for targeted treatment. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 649-652.	2.4	4
376	Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia?. <i>Blood</i> , 2006, 107, 4975-4977.	1.4	4
377	Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): Single-agent therapeutic window study in relapsed AML. <i>Pediatric Blood and Cancer</i> , 2006, 47, 539-542.	1.5	4
378	Value of routine bone marrow examination in pediatric acute myeloid leukemia (AML): A study of the Dutch Childhood Oncology Group (DCOG). <i>Pediatric Blood and Cancer</i> , 2012, 59, 1239-1244.	1.5	4

#	ARTICLE	IF	CITATIONS
379	Diversity in renal function monitoring and dose modifications during treatment for childhood cancer: A call for standardization. <i>Pediatric Blood and Cancer</i> , 2014, 61, 337-344.	1.5	4
380	¹⁸ F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma. <i>EJNMMI Research</i> , 2014, 4, 8.	2.5	4
381	Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 911-7.	2.3	4
382	Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma. <i>Oncotarget</i> , 2017, 8, 78978-78988.	1.8	4
383	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. <i>Eancermedalscience</i> , 2021, 15, 1187.	1.1	4
384	Complementary and alternative medicine in children with diffuse intrinsic pontine glioma: A SIOPE DIPG Network and Registry study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29061.	1.5	4
385	Treatment Outcome of Children with Retinoblastoma in a Tertiary Care Referral Hospital in Indonesia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1613-1621.	1.2	4
386	Childhood acute lymphoblastic leukemia treatment in an academic hospital in Kenya: Treatment outcomes and health care providers' perspectives. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29366.	1.5	4
387	Large Interindividual Differences in In Vitro Calicheamicin Sensitivity May Underly Gemtuzumab Ozogamicin Resistance in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2005, 106, 107-107.	1.4	4
388	Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya. <i>Cancer Reports</i> , 2022, 5, e1576.	1.4	4
389	Pediatric leukemia in the new millennium. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 1-2.	2.4	3
390	Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 322-327.	2.3	3
391	Psychiatric symptoms causing delay in diagnosing childhood cancer: two case reports and literature review. <i>European Child and Adolescent Psychiatry</i> , 2013, 22, 443-450.	4.7	3
392	Absence of <i>SBDS</i> mutations in sporadic paediatric acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 559-561.	2.5	3
393	Management of Children with Wilms Tumor in Africa and Europe; Thoughts About Costs, Priorities and Collaboration. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 395-399.	0.8	3
394	Re-induction with L-DNR/FLAG Improves Response after AML Relapse, but not Long-term Survival. <i>Klinische Padiatrie</i> , 2014, 226, 323-331.	0.6	3
395	Wilms tumour in Malawi: Surgical staging to stratify postoperative chemotherapy?. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2180-2184.	1.5	3
396	Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23). <i>Leukemia</i> , 2014, 28, 1564-1568.	7.2	3

#	ARTICLE	IF	CITATIONS
397	Clinical and prognostic significance of eosinophilia and inv(16)/t(16;16) in pediatric acute myelomonocytic leukemia (AML-M4). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26512.	1.5	3
398	Parental sleep after induction therapy for childhood acute lymphoblastic leukemia. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2021, 3, e045.	0.5	3
399	Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. <i>British Journal of Haematology</i> , 2021, 194, 423-432.	2.5	3
400	Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2025-2031.	1.2	3
401	Wilms's Tumor 1 Gene Mutations in Childhood Acute Myeloid Leukemia: A New Prognostic factor with Implications for MRD Detection. <i>Blood</i> , 2008, 112, 144-144.	1.4	3
402	Gemtuzumab Ozogamicin In Refractory Childhood Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1075-1075.	1.4	3
403	High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. <i>Blood</i> , 2012, 120, 888-888.	1.4	3
404	A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2634-2634.	1.4	3
405	Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates. <i>Blood</i> , 1999, 94, 3121-3128.	1.4	3
406	Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia. <i>Oncology Reports</i> , 2003, 10, 2027-31.	2.6	3
407	Health-care providers' perception and communication about traditional and complementary medicine in childhood cancer in Indonesia. <i>Pediatric Hematology Oncology Journal</i> , 2022, 7, 4-9.	0.1	3
408	Prevalence of Sleep Disorders, Risk Factors and Sleep Treatment Needs of Adolescents and Young Adult Childhood Cancer Patients in Follow-Up after Treatment. <i>Cancers</i> , 2022, 14, 926.	3.7	3
409	An evaluation of the disparities affecting the underdiagnosis of pediatric cancer in Western Kenya. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29768.	1.5	3
410	Insomnia Symptoms and Daytime Fatigue Co-Occurrence in Adolescent and Young Adult Childhood Cancer Patients in Follow-Up after Treatment: Prevalence and Associated Risk Factors. <i>Cancers</i> , 2022, 14, 3316.	3.7	3
411	Towards individualised treatment in childhood leukaemia. <i>Lancet Oncology</i> , The, 2010, 11, 502-503.	10.7	2
412	Adequate endocrine and cardiovascular response to social stress in survivors of childhood acute lymphoblastic leukemia. <i>Psychoneuroendocrinology</i> , 2013, 38, 3145-3149.	2.7	2
413	Combining Clofarabine and Fludarabine with Exposure Targeted Busulfan for Pediatric Leukemia: An Effective, Low Toxicity TBI-Free Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S99-S100.	2.0	2
414	Communication about Traditional Complementary and Alternative Medicine (TCAM) in childhood cancer: A comparison between Dutch and Indonesian health-care providers at academic hospitals. <i>Advances in Integrative Medicine</i> , 2020, 7, 89-95.	0.9	2

#	ARTICLE	IF	CITATIONS
415	Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 1346-1346.	1.1	2
416	Resistance Testing and Mechanisms of Resistance in Childhood Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 1999, 457, 391-395.	1.6	2
417	Lack of Cross-Resistance Between Prednisolone and Methotrexate in Childhood Acute Lymphoblastic Leukemia?. <i>Advances in Experimental Medicine and Biology</i> , 1999, 457, 551-555.	1.6	2
418	NF1 Microdeletions in Pediatric MLL-Rearranged AML and T-ALL: A Novel Mechanism for RAS Activation.. <i>Blood</i> , 2007, 110, 757-757.	1.4	2
419	Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01. <i>Blood</i> , 2010, 116, 184-184.	1.4	2
420	Risk-Group Stratified and Minimal Residual Disease (MRD)-Guided Treatment with Extended ATRA and Reduced-Anthracycline Chemotherapy in Childhood Acute Promyelocytic Leukemia (APL): Results from ICC APL Study 01 (NCT01226303; EudraCT 2008-002311-40). <i>Blood</i> , 2015, 126, 563-563.	1.4	2
421	A phase II study of single-agent gemtuzumab ozogamicin in relapsed/refractory pediatric acute myeloid leukemia (AML). <i>Journal of Clinical Oncology</i> , 2005, 23, 8524-8524.	1.6	2
422	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. <i>Blood</i> , 2010, 116, 762-762.	1.4	2
423	Interferon- β -Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harboring Bortezomib-Induced Mutations in Constitutive PSMB5. <i>Blood</i> , 2012, 120, 1346-1346.	1.4	2
424	Abstract 4437: The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia. <i>Cancer Research</i> , 2015, 75, 4437-4437.	0.9	2
425	Population Pharmacokinetics of Erwinia Asparaginase in Pediatric ALL Patients. <i>Blood</i> , 2015, 126, 1281-1281.	1.4	2
426	All It Takes for Corruption in Health Systems to Triumph, Is Good People Who Do Nothing Comment on "We Need to Talk About Corruption in Health Systems". <i>International Journal of Health Policy and Management</i> , 2019, 8, 610-612.	0.9	2
427	20 years of Expert Review of Anticancer Therapy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1-2.	2.4	2
428	Targeted monoclonal antibody-based treatment of hematological malignancies. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 253-255.	2.4	1
429	The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. <i>International Journal of Oncology</i> , 2004, 25, 1823.	3.3	1
430	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
431	In-Vitro Cytotoxicity of Tipifarnib (Zarnestra TM) in Pediatric AML and ALL Samples Is Independent of RAS Mutations.. <i>Blood</i> , 2004, 104, 1172-1172.	1.4	1
432	Sensitization of Leukemic Cells for Glucocorticoids by Inhibition of NF κ B Activity.. <i>Blood</i> , 2004, 104, 3395-3395.	1.4	1

#	ARTICLE	IF	CITATIONS
433	Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.. Blood, 2006, 108, 838-838.	1.4	1
434	Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells.. Blood, 2007, 110, 3469-3469.	1.4	1
435	Nucleophosmin Gene Mutations Identify a Favorable Risk Group in Childhood Acute Myeloid Leukemia with a Normal Karyotype.. Blood, 2007, 110, 366-366.	1.4	1
436	Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia.. Blood, 2008, 112, 1509-1509.	1.4	1
437	Liposomal Daunorubicin Causes Only Low Cardiotoxicity in Pediatric AML Patients.. Blood, 2008, 112, 1940-1940.	1.4	1
438	Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.. Blood, 2009, 114, 1624-1624.	1.4	1
439	Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ. Blood, 2014, 124, 2290-2290.	1.4	1
440	Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium. Blood, 2014, 124, 989-989.	1.4	1
441	Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics. Blood, 2015, 126, 2501-2501.	1.4	1
442	The Relevance of Stem Cell Load at Diagnosis for the Development of Relapse in Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 2584-2584.	1.4	1
443	The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study. Blood, 2016, 128, 2896-2896.	1.4	1
444	Individualized Tumor Response (ITR) Profiling for Drug Selection in Tailored Therapy: Meta-Analysis of 1929 Cases of Leukemia and Lymphoma.. Blood, 2007, 110, 3471-3471.	1.4	1
445	VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.. Blood, 2009, 114, 997-997.	1.4	1
446	Treatment of Acute Myeloid Leukemia. Pediatric Oncology, 2011, , 121-160.	0.5	1
447	Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression. Blood, 2011, 118, 1513-1513.	1.4	1
448	The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance. Blood, 2013, 122, 3841-3841.	1.4	1
449	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. Blood, 2015, 126, 172-172.	1.4	1
450	Health insurance coverage for vulnerable children: two HIV orphans with Burkitt lymphoma and their quest for health insurance coverage in Kenya. BMJ Case Reports, 2020, 13, e230508.	0.5	1

#	ARTICLE	IF	CITATIONS
451	Global Problem of Hospital Detention Practices. International Journal of Health Policy and Management, 2020, 9, 319-326.	0.9	1
452	A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused Ultrasound System for Blood-Brain Barrier Opening in Rodents. Journal of Visualized Experiments, 2020, , .	0.3	1
453	Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study. Cancers, 2022, 14, 3172.	3.7	1
454	Use of the Differential Staining Cytotoxicity Assay to Predict Chemosensitivity. , 2005, 110, 049-058.		0
455	Wnt-WNT pathway in ALL. Blood, 2007, 109, 3135-3136.	1.4	0
456	Progression From Free Floating Left Ventricular Vegetation to Immobile Mitral Valve in a Child With Zygomycetes Endocarditis. Infectious Diseases in Clinical Practice, 2009, 17, 268-269.	0.3	0
457	Old drug, new lessons. Blood, 2009, 113, 4480-4481.	1.4	0
458	Acute lymphoblastic leukaemia in children – is there a role for MTHFR? – response to Lightfoot <i>et al</i>. British Journal of Haematology, 2010, 149, 799-800.	2.5	0
459	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Yearbook of Oncology, 2011, 2011, 157-158.	0.1	0
460	Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood cancer and cancer in the reproductive age. The Cochrane Library, 0, , .	2.8	0
461	Novel estimating equation of GFR in children without height information performs as well as the Schwartz equation. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 8-8.	0.0	0
462	Glucocorticoid induced adrenal suppression in childhood acute lymphoblastic leukemia. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 46-46.	0.0	0
463	Het voorspellen van de gevoeligheid van kinderleukemiecellen voor proteasoomremmers. Tijdschrift Voor Kindergeneeskunde, 2014, 82, 79-88.	0.0	0
464	ME-04 * SUBVENTRICULAR SPREAD OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2014, 16, v120-v120.	1.2	0
465	An 8-Year-Old Girl with Ocular Swelling. Journal of Pediatrics, 2017, 181, 324-324.e1.	1.8	0
466	DIPG-15. EFFECTIVE PRECLINICAL TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA BY MELK INHIBITION. Neuro-Oncology, 2017, 19, iv7-iv8.	1.2	0
467	ATRT-19. PRECLINICAL EFFICACY OF COMBINED INHIBITION OF MEK AND MELK IN ATYPICAL TERATOID/RHABDOID TUMORS. Neuro-Oncology, 2018, 20, i31-i31.	1.2	0
468	DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i49-i50.	1.2	0

#	ARTICLE	IF	CITATIONS
469	Sensitivity and Cross-Resistance to Deoxynucleoside Analogs in Childhood Acute Leukemia.. Blood, 2004, 104, 2086-2086.	1.4	0
470	Methotrexate in Relapsed Childhood Acute Myeloid Leukemia: A Single Agent Therapeutic Window Study.. Blood, 2004, 104, 4509-4509.	1.4	0
471	Favorable Interactions between Aplidin (Plitidepsin) and Conventional Anticancer Agents in Leukemic Cell Lines and Acute Leukemia Patient Samples.. Blood, 2005, 106, 4442-4442.	1.4	0
472	Absence of JAK2 V617F Activating Mutations in Children with Acute Megakaryoblastic Leukemia with and without Down Syndrome.. Blood, 2006, 108, 4325-4325.	1.4	0
473	FLT3 and KIT Mutated Pediatric Acute Myeloid Leukemia (AML) Samples Are More Sensitive In Vitro to the Tyrosine Kinase Inhibitor SU11657.. Blood, 2006, 108, 1359-1359.	1.4	0
474	Hypermethylation of FANCC and FANCL Resulting in a Mitomycin-C (MMC) Sensitive Cellular Phenotype in Sporadic Acute Leukemia.. Blood, 2006, 108, 2224-2224.	1.4	0
475	Methylation of the PTPNS1 Promoter Region in Pediatric Acute Promyelocytic Leukemia.. Blood, 2007, 110, 4315-4315.	1.4	0
476	Potential for Cure by Chemotherapy Only, without Allogeneic Stem Cell Transplantation, in Pediatric Relapsed Acute Myeloid Leukemia?.. Blood, 2007, 110, 2865-2865.	1.4	0
477	Differences in Cyto- and Molecular Genetic Abnormalities between Children <2 Years and Older Children with Acute Myeloid Leukemia.. Blood, 2007, 110, 1830-1830.	1.4	0
478	Ex Vivo Activity of Bortezomib and Dexamethasone Combinations Against Childhood Acute Leukemia Cells.. Blood, 2007, 110, 4205-4205.	1.4	0
479	EVII Overexpression in Pediatric Acute Myeloid Leukemia Associated with Unfavorable Subtypes.. Blood, 2008, 112, 1802-1802.	1.4	0
480	Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.. Blood, 2008, 112, 963-963.	1.4	0
481	Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse. Blood, 2008, 112, 2540-2540.	1.4	0
482	Characterization of CEBPA Mutations and Promoter Hypermethylation in Pediatric Acute Myeloid Leukemia.. Blood, 2009, 114, 1605-1605.	1.4	0
483	High Frequency of Copy Number Variations in Myeloid Leukemia of Down Syndrome.. Blood, 2009, 114, 3242-3242.	1.4	0
484	Overexpression of BRE in Pediatric MLL-Rearranged Acute Myeloid Leukemia Associated with t(9;11)(p22;q23).. Blood, 2009, 114, 3471-3471.	1.4	0
485	The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.. Blood, 2009, 114, 940-940.	1.4	0
486	High IGSF4 expression In Pediatric Acute Monoblastic Leukemia with t(9;11). Blood, 2010, 116, 3614-3614.	1.4	0

#	ARTICLE	IF	CITATIONS
487	Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse. Blood, 2010, 116, 751-751.	1.4	0
488	Clinical and Prognostic Significance of Eosinophilia and Inv(16)/t(16;16) In Pediatric Acute Myelomonocytic Leukemia (AML-M4).. Blood, 2010, 116, 1664-1664.	1.4	0
489	Abstract 3461: A chemical screen for the identification of novel therapeutics for pediatric brain tumors. , 2011, , .		0
490	Abstract 3209: Gene expression micro array analysis of diagnosis and matched relapse pediatric AML samples indicates that immune regulatory pathways and epigenetic factors are involved in disease progression. , 2011, , .		0
491	Abstract 3462: PARP inhibition sensitizes high grade childhood brain tumors to radiation. , 2011, , .		0
492	Glucocorticoid-Induced Proliferation and Differentiation of Untreated Pediatric AML Cells. Blood, 2011, 118, 4873-4873.	1.4	0
493	Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML. Blood, 2012, 120, 283-283.	1.4	0
494	Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study. Blood, 2012, 120, 884-884.	1.4	0
495	Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.. Blood, 2012, 120, 2480-2480.	1.4	0
496	Telomere Length and Telomerase Complex Mutations in Pediatric Acute Myeloid Leukemia. Blood, 2012, 120, 1482-1482.	1.4	0
497	Low Levels of Mir-151-5p and Mir-451 Predict Relapse in Pediatric B-Lineage Acute Lymphoblastic Leukemia.. Blood, 2012, 120, 2507-2507.	1.4	0
498	Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia with Pegasparginase and Erwinia Asparaginase: The Impact of Expensive Chemotherapy. Blood, 2012, 120, 4227-4227.	1.4	0
499	Abstract 4628: Alterations in FPGS splicing as a plausible underlying mechanism of MTX resistance in ALL. , 2013, , .		0
500	Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid. Blood, 2013, 122, 1439-1439.	1.4	0
501	Abstract 3775: Identification of PHF6 as a temozolomide resistance factor in glioblastoma using mirConnX. , 2014, , .		0
502	Abstract LB-169: Ratios of immunoproteasome over constitutive proteasome expression are an indicator for sensitivity to bortezomib-containing reinduction chemotherapy in pediatric relapsed ALL and AML. , 2014, , .		0
503	Abstract 4764: Transfer of regulatory protein networks via extracellular vesicles as a candidate mechanism of apoptosis-resistance in acute myeloid leukemia. , 2014, , .		0
504	Abstract B34: Increased risk of relapse in non-high-risk children with pediatric B-lineage acute lymphoblastic leukemia can be predicted at diagnosis by microRNA expression. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
505	Genetic Aberrations As Putative MRD Targets in Childhood Acute Myeloid Leukaemia. Blood, 2014, 124, 2331-2331.	1.4	0
506	Prediction of Relapse By microRNA Expression in Pediatric B-Lineage Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3793-3793.	1.4	0
507	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. Blood, 2014, 124, 481-481.	1.4	0
508	Abstract 1624: Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. , 2015, , .		0
509	Glucocorticoid-Induced Proliferation and Lack of Differentiation in Untreated Pediatric Acute Myeloid Leukemic Blasts. Blood, 2015, 126, 4843-4843.	1.4	0
510	Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. Blood, 2015, 126, 3712-3712.	1.4	0
511	Abstract B27: Toxicity of convection-enhanced delivery with doxorubicin to treat pediatric brain-tumors depends on anatomical location. , 2015, , .		0
512	Abstract 4336: Spliceosome inhibition as a novel therapeutic option in acute leukemia. , 2016, , .		0
513	Abstract 332: Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma. , 2016, , .		0
514	Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma. Blood, 2018, 132, 5200-5200.	1.4	0
515	Cumulative Incidence of Blood Stream Infections during Acute Myeloid Leukemia Treatment in the Netherlands: A 15-Year Overview. Blood, 2018, 132, 2685-2685.	1.4	0
516	Deregulation of Splicing in Pediatric Acute Myeloid Stem and Progenitor Cells. Blood, 2021, 138, 2227-2227.	1.4	0
517	Increased Survival Disparities Among Children and Adolescents & Young Adults with Acute Myeloid Leukemia: A Dutch Population-Based Study. Blood, 2021, 138, 845-845.	1.4	0
518	PATH-04. THE BLOOD-BRAIN BARRIER IN DIFFUSE MIDLINE GLIOMA AND ITS IMPLICATIONS FOR DRUG DELIVERY. Neuro-Oncology, 2020, 22, ii164-ii164.	1.2	0
519	Long-Term Tubular Dysfunction in Childhood Cancer Survivors; DCCSS-LATER 2 Renal Study. Cancers, 2022, 14, 2754.	3.7	0